ArticleJournal of hepatocellular carcinoma2026
A Novel Predictive Model Based on Glutathione Metabolism Genes RRM2 and G6PD in Hepatocellular Carcinoma.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Glutathione (GSH) metabolism is closely associated with tumor behavior in hepatocellular carcinoma (HCC). HCC is the third fatality reason and the sixth incidence rank in global tumor ranking. Our study explored the connection between glutathione metabolism genes (GMGs) expression and HCC progression and prognosis. Methods: We obtained seven differentially expressed genes (DEGs) by analyzing GMGs dataset in HCC and the TCGA-LIHC cohort. Utilizing LASSO Cox analysis, we developed a predictive model based on 2-GMGs: Ribonucleotide reductase regulatory subunit M2 (RRM2) and glucose-6-phosphate dehydrogenase (G6PD). The model was apprized with the SHapley Additive exPlanations (SHAP). The predictive ability of the model was rigorously validated through prognostic stratification, univariable and multivariable Cox regression, and nomogram construction. We anticipated chemotherapy sensitivity using the GDSC database and used GEPIA and TIMER to examine the correlations with 2-GMGs expression and cellular immune-associated markers. This study also detects the impact of RRM2 and G6PD expression on HCC patient survival through immunohistochemistry. Results: A prognostic model and nomogram composed of 2-GMGs provided an accurate prognostic for HCC patients. The median risk score as a dividing criterion was used to classify into low and high-risk groups. A positive outcome for the lowest-risk group was achieved by Kaplan-Meier curves. Moreover, the risk score was verified as an independable predictive indicator by multifactorial and unifactorial Cox regression analyses. Notable disparities between the two groups regarding the infiltration of different immune cell subtypes, tumor mutation burden (TMB) and sensitivity to chemotherapeutic subtypes were observed. Finally, immunohistochemical indicated that increased RRM2 and G6PD expression and decreased viability of HCC patients. Conclusion: Our findings exposit that the higher 2-GMGs expression and the worse progression and prognosis of HCC. The SHAP approach was employed to elucidate the 2-GMGs model, enhancing its utility for clinicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.